Amplification and mutation of the epidermal growth factor receptor (EGFR) is common in astrocytoma. The most frequently occurring mutation (DEGFR, EGFRvIII) deletes exons 2-7 from this receptor tyrosine kinase (RTK), and signals constitutively in the absence of ligand. DEGFR is not found in normal tissue, and therefore represents an attractive therapeutic target. Here, we show that a small interfering RNA (siRNA) directed against the unique exon 1/exon 8 junction sequence of DEGFR efficiently suppressed expression of DEGFR in rodent fibroblasts and in two human glioblastoma cell lines. SiRNA-mediated depletion of DEGFR led to reduction in the levels of phosphorylated Akt in glioma cells, was associated with increased apoptosis, and induced partial arrest at the G 2 M phase of the cell cycle. Inhibitors of PI3 kinase cooperated with siRNA treatment, leading to further increases in both cell cycle blockade and apoptosis. Importantly, cell cycle blockade could be reversed, and apoptosis rescued using a conditional allele of Akt, implicating Akt as a primary target of combination therapy. This study demonstrates the therapeutic potential of siRNA to impact DEGFR as a glioma-specific target, and offers a mechanistic rationale for combining siRNA and small molecule inhibitor therapies against distinct components in the EGFR signaling pathway.
Introduction
Astrocytomas are the most common primary brain tumor in adults, and the most frequently occurring solid tumor of childhood. Astrocytomas are graded according to histological changes including proliferation, atypia, necrosis and microvascular proliferation, and include astrocytomas (WHO Grade II), anaplastic astrocytomas (WHO Grade III), and glioblastoma multiforme (GBM -WHO Grade IV) in order of increasing malignancy. GBM, the most common astrocytoma, may progress secondarily from pre-existing lower grade tumors, or may arise de novo as primary GBM, especially in older patients. The median survival of patients with GBM has remained less than 1 year despite concerted efforts to improve current therapies and develop novel clinical approaches (DeAngelis, 2001) .
Amplification of EGFR occurs in approximately 40% of astrocytomas and correlates with advanced disease (Wong et al., 1987; Humphrey et al., 1988) . The amplified EGFR is commonly mutated (Ekstrand et al., 1992 (Ekstrand et al., , 1994 Wong et al., 1992) . The most commonly occurring tumor-associated allele of EGFR (DEGFR or EGFRvIII, or de2-7EGFR) deletes 267 amino acids in the extracellular domain of EGFR, constituting the entirety of exons 2-7, and shows constitutive kinase activity independent of ligand binding Ekstrand et al., 1992; Wong et al., 1992) . EGFR is amplified in approximately half of GBM, and the DEGFR allele is found in approximately half of these amplicons Humphrey et al., 1990; Sugawa et al., 1990) .
As it is implicated in such a large number of malignancies, epidermal growth factor receptor (EGFR) provides an attractive target for anticancer therapy. A monoclonal antibody raised against DEGFR recognizes DEGFR and some of the wild-type EGFR in tumor cells that overexpress the wild-type receptor, and demonstrated antitumor activity against human xenografts expressing DEGFR, or overexpressing wild-type EGFR (Luwor et al., 2001; Johns et al., 2002) . In addition, two tricyclic quinazolines showed inhibition in the nM range for EGF-mediated receptor autophosphorylation, and have been tested in clinical trials. ZD1839 (Iressa) had only modest activity in lung cancer, and was most efficacious in patients whose cancers showed activating mutations in EGFR (Ranson et al., 2002; Lynch et al., 2004; Paez et al., 2004) . did extend life in patients with lung cancer (ASCO 2004 abstract #7022; Shepherd et al.;  http://www.asco.org/ ac/1,1003,_12-002643-00_18-0026-00_19-00678,00.asp) (Hidalgo et al., 2001) . ZD1839 showed some activity against glioma in a recent phase 2 trial (Rich et al., 2004) .
A monoclonal antibody to the peptide created by joining exons 1 and 8 of EGFR detected DEGFR in >50% of human cancer specimens from oligodendroglioma, medulloblastoma, breast, ovarian, lung, and prostate, but not in normal tissue. Since DEGFR is detected commonly in a variety of human cancers, targeting this tumor-specific target may allow more selective therapeutic strategies (and potentially a more favorable side effect profile) than are possible using small molecule inhibitors of EGFR.
RNA interference (RNAi) was first described in Caenorhabditis elegans through studies showing that exogenous double-stranded RNAs could induce gene silencing (Grishok et al., 2001; Ketting et al., 2001; Knight and Bass, 2001 ). These double-stranded RNAs are processed into small interfering RNAs (siRNAs) and mediate the suppression of homologous genes through a phylogenetically conserved cellular pathway. The application of this technology towards signaling molecules active in cancer has recently been shown to ameliorate the transformed phenotype in cells dependent on p53, ras, and BCR/ABL (Williams et al., 2001; Brummelkamp et al., 2002a, b; Wilda et al., 2002; Hemann et al., 2003; Kunath et al., 2003) . We report that DEGFR can be specifically inactivated in human glioma cell lines, through the use of siRNA directed against the unique junction sequence in this tumor-specific allele.
Results
An siRNA against the unique exon 1/exon 8 junction sequence abrogates expression of DEGFR, leading to apoptosis, and proliferation arrest at G 2 M We designed a 21-base double-stranded oligoribonucleotide in which the first seven nucleotides were derived from the 3 0 end of exon 1 of EGFR, and the remaining 14 nucleotides were derived from the 5 0 end of exon 8 ( Figure 1a ). Transfection of a DEGFR-specific siRNA into murine fibroblasts, and into two human glioblastoma cell lines engineered to overexpress this receptor resulted in substantial reduction or absence of detectable DEGFR (Figure 1b-f) . Analysis of mRNA levels using reverse transcription-PCR (RT-PCR) demonstrated a marked decrease in mRNA for DEGFR (Figure 1c) . The inhibitory effect of this siRNA showed marked specificity. The siRNA did not impact expression of wild-type EGFR, and a control siRNA mismatched at two positions had no effect on expression of DEGFR ( Figure 1d ). As a surrogate of DEGFR activity, we analysed phosphorylation of DEGFR using antibodies to total cellular phospho-tyrosine, or to phospho-EGFR. In response to siRNA treatment, the phosphospecific form of DEGFR was nearly undetectable by both of these analyses (Figure 1) .
To analyze the functional impact of DEGFR deficiency in glioma cell lines, we labeled cells with propidium iodide (PI), and analysed cell cycle progression. Treatment of U87:DEGFR or U373:DEGFR cells with siRNA directed against DEGFR increased the fraction of cells at G 2 M, and left the proportion of cells in S phase either slightly increased (Figure 2a ) or unchanged (Figure 3a) , consistent with partial arrest at the G 2 M phase of the cell cycle. Although lipofectamine treatment alone increased the G 2 M fraction for U87:DEGFR cells (Figure 2 ), siRNA treatment led to further increases in G 2 M (Figure 2 (Figures 2 and 3 ). Neither siRNA nor ZD1839 showed appreciable toxicity in vitro at concentrations shown.
SiRNA treatment also impacted the sub-G 1 fraction (Figure 5a and c), demonstrating increased apoptosis in response to siRNA directed against DEGFR. Mean value for sub-G 1 fraction in three replicates of U373:DEGFR cells was 3% for mismatch siRNA vs 8.3% for siRNA treatment (Po0.0001). To further analyse the impact of siRNA treatment on apoptosis, U373:DEGFR were treated with siRNA against DEGFR, or with a mismatched siRNA, and analysed by TUNEL. These data (Figure 5b ) also demonstrated an increase in apoptosis in siRNA-treated U373:DEGFR cells. Comparable results for sub-G 1 fractionation were also observed in siRNA treated U87:DEGFR cells (Figure 5d ). Mean value for sub-G 1 fraction in three replicates of U87:DEGFR cells were 5.5% for mismatch siRNA vs 7.7% for siRNA treatment (Po0.005).
SiRNA treatment of glioblastoma cell lines impacts signaling through PI3 and MAP kinases
Signaling by EGFR is mediated primarily by MAP kinase and phosphatidylinositol 3 (PI3) kinase pathways (reviewed in Schlessinger, 2000) . To analyse the impact of siRNA treatment on signaling by DEGFR, we treated U87:DEGFR or U373:DEGFR cells with siRNA against DEGFR, and analysed signaling using antibodies to signaling intermediates in the MAP and PI3 kinase pathways. Levels of phospho-Akt and phospho-Erk increased after introduction of DEGFR into these cell lines ( Figure 5a ). In response to siRNA treatment, levels of phospho-Akt were reduced to levels comparable to those observed in the parental cell lines lacking DEGFR. Levels of phospho-Erk were reduced in U373:DEGFR cells to a greater extent than in U87:DEGFR cells ( Figure 5a ). To further characterize the impact of siRNA treatment on signaling through DEGFR, we measured the activities of MAP and Akt kinases using Elk1 and Gsk-3a/b-derived substrates. Figure 5b shows that siRNA treatment impacted Akt and Erk activity in both cell types.
Inhibitors of PI3 kinase cooperate with siRNA treatment in glioblastoma cells
Since PI3 kinase signaling has been shown to impact transition through the G 2 M stage of the cell cycle (Shtivelman et al., 2002) , we asked whether therapy using siRNA in combination with a small molecule inhibitor of PI3 kinase could cooperate in blocking progression through the cell cycle. Figures 2 and 3 shows that the PI3 kinase inhibitor LY294002 cooperated with an siRNA against DEGFR to induce cell cycle blockade at G 2 M. Mean values for G 2 M fraction in three replicates of siRNA þ LY294002 treatment vs mismatch siRNA þ LY294002 were 2.6 vs 14.9% (Po0.0001) for U87:DEGFR cells, and 37 vs 54.4% (Po0.0001) for U373:DEGFR cells. Western analysis showed that combination therapy with LY294002 and siRNA led to a reduction in levels of phospho-Akt to a greater extent than that achieved using either agent as monotherapy (Figures 2b and 6a ). Since stabilization and nuclear transport of the Cdk-inhibitor p27 Kip1 occurs in response to PI3 kinase inhibition, and may contribute to cell cycle arrest in glioma cells (Gottschalk et al., 2001) , we analysed levels and nuclear fractionation of p27 in response to siRNA treatment. These results demonstrated increased levels of p27 in the nucleus in response to siRNA treatment ( Figure 3b ).
PI3 kinase signaling also impacts apoptosis. We therefore analysed the sub-G 1 fraction in U373:DEGFR cells treated with LY294002 þ siRNA against DEGFR. Figure 4a-d shows that combination therapy led to increased levels of apoptosis in comparison with levels achieved using either therapy alone. Mean values for sub-G1 fraction in three replicates of mismatch siR-NA þ LY294002 treatment vs siRNA þ LY294002 were 4.8 vs 12.3% (Po0.001) in U373:DEGFR cells, and 7.2 vs 11.7% (Po0.0001) in U87:DEGFR cells. Whether this modest increase in apoptotic fraction will translate into a meaningful clinical perspective is uncertain. However, to verify this result, we performed TUNEL analysis in U373:DEGFR cells using mismatch siRNA þ LY294002, or LY294002 in combination with siRNA directed against DEGFR (Figure 4a ). Again, combination therapy led to increased levels of apoptosis, demonstrating cooperativity between siRNA therapy and PI3 kinase inhibition.
A conditional allele of Akt reverses G 2 M arrest, and rescues apoptosis in siRNA-treated cells Figures 2-5 demonstrated that an inhibitor of PI3 kinase could cooperate with an siRNA directed against DEGFR, inducing partial proliferation arrest and apoptosis in glioma cells. Data in Figure 5 suggest that these two approaches impacted levels and activity of of Akt kinase. To more precisely define the role of Akt blockade in growth arrest and apoptosis in these experiments, we asked whether proliferation could be restored through activating a conditional allele of Akt. We transduced U373:DEGFR cells with M þ Akt:ER*, a membrane targeted fusion protein Cells were harvested, lysed, and subjected to immunoblot analysis using the indicated antibodies. Comparable data were generated using U373MG cells transduced with vector or with DEGFR and treated with siRNA, LY294002, or both (data not shown) antibodies indicated consisting of a constitutively active form of Akt kinase fused to the hormone-binding domain of the mouse estrogen receptor (that binds 4 hydroxytamoxifen (4-HT) but is refractory to estrogen (Mirza et al., 2000) ).
Experiments in
Cyclin A levels rise in S phase and stay high until early mitosis. Cyclin B1 forms an inactive complex with Tyr-14, Tyr-15, and Thr-161-phosphorylated Cdc2 during S phase. This inactive complex continues to accumulate during G 2 until it is activated by dephosphorylation of Tyr-14 and Tyr-15 during mitosis (Morgan, 1997; Chow et al., 2003) . Figure 6a shows that levels of phosphorylated Cdc2 increased markedly, whereas levels of Cyclin A increased modestly in response to treatment with siRNA, or siRNA þ LY294002, suggesting that the arrest observed in treated U373:DEGFR/M þ Akt:ER occurred in G 2 rather in M phase. Treatment of these cells with 4-HT resulted in increased levels of M þ Akt:ER, and in phosphorylation of M þ Akt:ER on Ser-473 (Figure 6a) . Activation of M þ Akt:ER* in turn led to decreased levels of phosphorylated Cdc2 (on Tyr-15), reversing the biochemical changes observed after treatment with siRNA or siRNA plus LY294002. Interestingly, activation of M þ Akt:ER was associated both with phosphorylation of this protein, and with a relative decrease in the phosphorylation of endogenous Akt (Figure 6a, compare lanes 5 and 4) . The reasons for preferential phosphorylation of M þ Akt:ER at the expense of endogenous Akt are unknown, but could be related to the relative abundance of these two proteins, or to the constitutive association of M þ Akt:ER with the inner cell membrane.
Activation of M þ Akt:ER* rescued the partial cell cycle arrest associated with siRNA treatment alone, or in combination with LY294002. Comparable biochemical and cell cycle data were obtained after activating M þ Akt:ER* in U87:DEGFR cells treated with siRNA alone, or siRNA þ LY294002 (data not shown). Collectively, data presented in Figure 6 demonstrate that activation of Akt can reverse the cell cycle arrest associated with siRNA therapy alone, or in combination with LY294002, implicating Akt as the primary target of these therapies.
Discussion

SiRNA directed against DEGFR as a tumor-specific target
Amplification of EGFR is common in glioma, correlating with advanced disease and poor outcome. Inhibitors of EGFR are showing promise in inducing remission in these patients, however such remissions are generally not durable (ASCO 2003 abstract #394; Prados et al.; http://www.asco.org/ac/1,1003,_12-002490-00_18-002003-00_19-00102386,00.asp; Mike Prados, personal communication). Compounding these matters, patients who best respond to inhibitors of EGFR generally develop a rash that can be severe, a likely side effect of Figure 6 Reversal of G 2 M arrest using a conditional allele of Akt. U373MG cells were transduced with DEGFR and with an allele of Akt that is membrane associated (through fusion to the c-Src myristylation targeting sequence), and that can be activated by addition of 4-HT (through fusion to the hormone-binding domain of the mouse estrogen receptor). Cells were subsequently transfected with mmsiRNA or siRNA, and treated with LY294002 (5 mM), or with 4HT (500 nM) as indicated. (a) Cells were harvested, lysed, and subjected to immunoblot analysis using the antibodies shown. (b) Cells were trypsinized, stained with PI and subjected to flow cytometric analysis. Bar graphs show percentage of cells in G 0 G 1 , S, and G 2 M Figure 5 SiRNA treatment of glioblastoma cell lines leads to decreased signaling through MAP and PI3 kinases. (a) Western blot showing U87MG or U373MG cells stably transduced with pLRNL vector control, or with DEGFR cloned into pLRNL-neo. Cells were transfected with 80 nM siRNA per well (six well plate), and lysates blotted with the antisera indicated. SiRNA treatment led to reduction in P-Akt levels, and more modest reductions in levels of P-Erk. (b) MAP and Akt kinase activities in response to siRNA treatment. Cells treated as in (a) were lysed, and 300 mg of protein was immunoprecipitated with immobilized antibodies that bind to either MAP or Akt kinase, respectively. Activities of the immobilized precipitated kinases were then measured using Elk-1 (for MAPK) and Gsk-3a/b (for Akt) as substrates, followed by immunoblot analysis using phosphospecific antibodies inhibiting EGFR in the skin (Hansen et al., 1997) . Thus, the use of EGFR inhibitors in the treatment of glioma, while promising, remains problematic, and leaves open the need for additional therapeutic approaches, especially selective approaches directed at tumor-specific alleles of EGFR. Towards this end, a monoclonal antibody that recognizes DEGFR and a subset of wild-type EGFR was effective in xenograft models of this disease (Luwor et al., 2001; Johns et al., 2002) . Consistent with these reports, we have shown here that siRNA-mediated silencing of DEGFR is specific and effective in blocking growth of glioma cells in vitro. Unlike the small molecule inhibitors and the monoclonal antibody described above, this siRNA does not impact EGFR, but rather is selective for the DEGFR mRNA.
Cell cycle arrest and apoptosis in DEGFR-treated cells
Treatment of glioma cell lines using siRNA against DEGFR resulted in a decreased S phase fraction, an increased the G 2 M fraction consistent with a partial G 2 M arrest, and a mild increase in G 0 G 1 fraction, consistent also with partial G 0 G 1 arrest. These data stand in slight contrast to similar studies using small molecule inhibitors of EGFR in glioma cell lines, which generally led to arrest in G 1 S (Peng et al., 1996; Wu et al., 1996; Busse et al., 2000) . As a consequence of siRNA-mediated arrest at G 2 M, the fraction of cells in G 1 S cells would be depleted as cells continue to pass into S phase, and cells are unable to pass into G1 due to cell cycle block in that phase. Since the fraction of cells in G 1 S actually increases slightly in response to this siRNA (Figures 2 and 3) , it is likely that this treatment induces arrest both at G 1 S and at G 2 M.
Since blockade of PI3 kinase signaling is also known to impact transition through the G 2 M stage of the cell cycle (Shtivelman et al., 2002) , we assessed changes in PI3 kinase signaling resulting from siRNA treatment, demonstrating that siRNA treatment led to reduced levels of phospho-AKT. SiRNA treatment also led to increased apoptosis. Both the cell cycle arrest and the apoptosis were rescued by a conditional allele of Akt. Although the mechanistic basis through which Akt blockade leads to proliferation arrest is currently unknown, Akt mediates apoptosis at least in part through phosphorylation of the proapoptotic factors BAD and Casp9 (Datta et al., 1997; del Peso et al., 1997; Cardone et al., 1998) . Based on our observations, and on the known role for Akt in mediating apoptosis, we hypothesize that an siRNA targeted to DEGFR results in partial arrest at G 2 M and apoptosis, and that these cell cycle perturbations are mediated primarily through decreased Akt signaling.
Combination therapy using siRNA and small molecule inhibitors to impact two nodes in a signaling pathway: implications for human cancer
The observation that an siRNA directed against DEGFR cooperates with a small molecule inhibitor of PI3 kinase raises intriguing issues regarding use of siRNA in clinical and preclinical settings. While blockade of DEGFR by siRNA is exquisitely specific, the interaction of LY294002 with PI3 kinase is relatively nonspecific. LY294002 inhibits a number of PI3 kinase isoforms. Activation of PI3 kinase in turn causes PDK1-mediated activation of Akt, a serine-threonine protein kinase. Akt phosphorylates a large number of substrates, including the growth-inhibitory protein glycogen synthase kinase 3 (GSK3), the forkhead transcription factor FKHLR1 (Cross et al., 1995; Biggs et al., 1999; Brunet et al., 1999) , and the TSC2 protein, which negatively regulates the translation regulatory protein mTOR (reviewed in Kwiatkowski, 2003) . Since small molecule inhibitors exist only for a limited number of known targets in the PI3 kinase signalling cascade, future experiments using siRNA against specific components of PI3 signalling, in combination with siRNA against DEGFR should clarify the contributions of specific targets to the cooperativity observed in combining siRNA against DEGFR with inhibitors of PI3 kinase, and may lead to mechanistic insights into the proliferation arrest observed using this combination therapy.
This study also demonstrates that the siRNA directed against DEGFR is highly sequence specific. A mismatched siRNA failed to recognize DEGFR, and the siRNA against DEGFR failed to block EGFR, despite having homology with regions of EGFR exons 2 and 8. This exquisite specificity also raises the possibility that tumor cells may escape siRNA therapy by mutation of the siRNA target sequence (Wilda et al., 2002) . Nevertheless, siRNA therapy, while suffering from the delivery issues of gene therapy, holds promise as a preclinical and potentially as a clinical reagent as it allows the targeting of signaling molecules for which no small molecule inhibitor has been developed. The use of siRNA as a preclinical reagent in mouse models of cancer should ultimately clarify the utility of this therapeutic modality in model organisms, and will provide information as to whether this approach can or should be applied in clinical cancer therapy.
Materials and methods
Cell culture, transfection, and transduction
Synthetic siRNAs ( Figure 1a) were purchased from Dharmacon Research, Inc., Lafayette, CO. Cells were transfected with siRNA using Lipofectamine 2000 (Invitrogen Corp., Carlsbad, CA, USA) as directed by the manufacturer. In brief, 1 day prior to transfection, cells were seeded in six-well plates at 5 Â 10 5 /cm 2 . SiRNAs were transfected at 80 nM (except in dosedependent experiments, in which concentrations of siRNA ranged from 40 to 160 nM. Cells were incubated with mmsiRNAs (mismatch siRNAs) plus lipofectamine, siRNAs plus lipofectamine, or lipofectamine alone for 5 h, washed once with PBS, and replated in fresh culture medium without lipofectamine or siRNA. All cells were cultured in phenol redfree Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin, and streptomycin at 371C in a humidified atmosphere containing 5% CO 2 . Although amplification of DEGFR is common in astrocytoma, this genetic lesion is not maintained in astrocytoma-derived cell lines (Libermann et al., 1985; Ekstrand et al., 1991; Wong et al., 1992) . U87MG and U373MG are human glioma cell lines that show increased malignancy in response to DEGFR (Nishikawa et al., 1994) (Webster Cavenee, personal communication) . We therefore transduced these cell lines with DEGFR for the experiments described. U87MG, U373MG, and NIH3T3 cells and their derivative cell lines U87:DEGFR, U87:EGFR, U373:DEGFR, NIH3T3:DEGFR, and a retroviral-based pLRNL-neo-DEGFR plasmid (Nishikawa et al., 1994) were kindly provided by Russ Pieper, UCSF. Plasmid pBabe M þ Akt:ER/puro (Mirza et al., 2000) was a gracious gift from Martin McMahon, UCSF. Retroviral constructs were transfected into Phoenix A or Bosc23 packaging cells using Effectene transfection reagent (Qiagen, Valencia, CA, USA). At 48 h post-transfection, the tissue culture medium was filtered through a 0.45 mm filter. Viral supernatants were used to infect of cells (24 h) in the presence of 8 mg/ml polybrene. Infected cells were selected as pools with G418 800 mg/ml or puromycin 1.8 mg/ml. 4-HT (Sigma Chemical Company, St Louis, MO, USA) was prepared as a 1 mM stock in ethanol, stored at À201C, and used at 500 nM/ml. ZD1839 was synthesized as described previously (Fan et al., 2003) .
Immunoblot analyses
Details of Western analyses are as previously described (Fan et al.,. 2002) . Membranes were blotted with one of the following antibodies: P-Erk (Thr202/Tyr204), P-Akt (Ser473), P-Cdc2 (Tyr15), and Akt (Cell Signaling, Beverly, MA, USA), P-EGFR (Tyr1173), cyclin D1, cyclin A, and ERK2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), b-tubulin, anti-phosphotyrosine, 4G10 (Upstate Biotechnology, Lake Placid, NY, USA), EGFR/DEGFR (Ab5, NeoMarkers, Fremont, CA, USA), p27 (BD Pharmingen, San Jose, CA, USA). Bound antibodies were detected with horseradish peroxidase-linked anti-mouse or anti-rabbit IgG (Amersham Pharmacia Biotech Arlington Heights, IL, USA), followed by enhanced chemiluminescence (Amersham Pharmacia Biotech Arlington Heights, IL, USA), and exposure to X-ray film.
RT-PCR
Total RNA was extended with TRIZOL (Invitrogen Corp, Carlsbad, CA, USA). Aliquots (2 mg) were DNase treated and processed for first-strand cDNA synthesis using the Reverse Transcription System Kit (Promega Corp, Madison, WI, USA). A 2 ml aliquot of each cDNA product was amplified by PCR using sense and antisense primers: EGFR/DEGFR 5 0 -primer, TGACTCCGTCCAGTATTGATCG and 3 0 -primer, ATTCCGTTACACACTTTGCGGC; glyceryladehyde 3-phosphate dehydrogenase (GAPDH) 5 0 -TTGAAGGGTG GAGCCAAACGGGTCA, 3 0 -primer, ACAGTCTTCTGGG TGGCAGTGATGG. PCR was carried out for 25 cycles (GAPDH) or 30 cycles (EGFR/DEGFR): 1 min 941C, 1 min at 601C, and 1 min at 721C.
In vitro kinase assays
Akt and MAPK kinase activities were assessed by determining the phosphorylation state of their respective substrates, Gsk3a/b and Elk-1, using nonradioactive assays (Cell Signaling, Beverly, MA, USA). Briefly, attached cells were treated or untreated with siRNA for 48 h and lysed. Equal amounts of protein (300 mg) were immunoprecipitated with immobilized antibodies that bind to either P-MAPK or P-Akt. The immobilized precipitated kinases were then used in kinase assays using Elk-1 (for MAPK) and Gsk-3a/b (for Akt) as substrates followed by immunoblot analysis using phosphospecific antibodies.
Flow cytometric analysis and cell cycle distribution Cells were plated at 5 Â 10 5 cells/cm 2 on six-well plates. For measurements of proliferation (Figures 2 and 3) , media was removed, cells were washed with PBS, and cells adherent to the plate were harvested. For measurement of sub-G1 fraction (Figure 4 ), nonadherent cells (from the growth media and PBS wash) were pooled with the adherent cells. For both analyses, cells were fixed in 70% ethanol on ice for 30 min, washed with PBS, treated with 5 mg/ml PI (Sigma Chemical Company, St Louis, MO, USA) containing 125 U/ml protease-free Rnase (Calbiochem, San Diego, CA, USA), filtered through 95 mM nylon mesh (Small Parts, Inc., Miami Lakes, FL, USA), and 10 000 stained nuclei were analysed in a FACS Calibur flow cytometer (Becton Dickinson, Mansfield, MA, USA). DNA histograms were modeled off-line using Modifit-LT software (Verity Software, Topsham, ME, USA).
Statistical analysis
Three independent studies were performed for each group of experiments. The statistical significance of the results was determined by the unpaired Students' t-test. A P-value of 0.05 or less was considered significant.
Induction and assessment of apoptosis by TUNEL
Cells were seeded in six-well plates at a density of 5 Â 10 5 /cm 2 and incubated for 48 h in the presence of siRNA or mmsiRNA, 7LY294002. TUNEL staining was performed using a DeadEndt Fluorometric TUNEL System Kit (Promega Corporation, Madison, WI, USA). Cells were cytospun onto slides, fixed in 4% paraformaldehyde at room temperature for 20 min, washed with PBS three times, and permeabilized for 5 min (0.1% Triton-X-100 in PBS). Equilibration buffer (100 ml) was added for 10 min, and cells were incubated in TUNEL reaction mixture (60 min, 371C) to label DNA strand breaks with fluorescein-12-dUTP. Nuclei were labeled with To-Pro-3 iodide (Molecular Probes, Eugene, OR, USA) for 30 min at room temperature. Cells were mounted with Vectashield mounting media (Vector Laboratories, Inc., Burlingame, CA, USA) as an antifade and >1000 cells were counted using a fluorescent microscope (TET300; Nikon, Tokyo, Japan) equipped with a confocal laser scanning system (MR-1024: Bio-Rad, Tokyo, Japan).
